Abstract: Currently, there are no effective preventive strategies for pancreatic cancer. Obesity has been increasingly recognized as a strong but modifiable risk factor of pancreatic cancer. In this article, we aim to review the literature regarding weight loss on prevention of pancreatic cancer. Epidemiological and laboratory studies have shown that obesity is associated with increased incidence of pancreatic cancer and potentially worse cancer outcome. Whereas the underlying pathomechanisms remain unclear, chronic inflammation, insulin resistance, and altered intestinal microbiota are all implicated in the carcinogenic effect of obesity. Weight loss, especially the durable and significant weight loss after bariatric surgery, has been shown to reduce the risks of multiple cancers and may become a good intervention for pancreatic cancer prevention.
Importantly, obesity has also been recognized as a major risk factor of multiple solid cancers. Epidemiological studies have linked obesity to an increased incidence of endometrial cancer, postmenopausal breast cancer, esophageal adenocarcinoma, colon cancer, hepatic cellular carcinoma, renal cell carcinoma, and prostate cancer. [3] [4] [5] [6] [7] [8] In particular, obesity has been associated with an increased incidence of pancreatic cancer, an almost universally lethal disease. [9] [10] [11] This review will discuss the link between obesity and pancreatic cancer and the benefits of weight loss in prevention of pancreatic cancer.
OBESITY AND PANCREATIC CANCER
Pancreatic cancer is currently the third leading cause of cancer death after lung and colorectal cancers. In United States, pancreatic cancer has an annual incidence of 48,960 and accounts for 40,560 cancer deaths in 2015. 12 It accounts for 3% of newly diagnosed cancers per year but 7% of cancer death per year. The incidence is rapidly growing, and it has been projected that by 2030 pancreatic cancer will surpass colorectal cancers to become the second leading cause of cancer death after lung cancer. 13 Complete surgical resection significantly prolongs survival; however, most pancreatic cancer patients are diagnosed at late stage with locally advanced disease or distant metastasis and only a small percentage of patients are surgical candidates. With marginnegative resection and negative lymph nodes, the 5-year survival can reach 40% at best at some large tertiary centers. [14] [15] [16] [17] However, the overall prognosis of all pancreatic cancer patients is dismal with a 5-year survival rate of 7.2%. 12 Large epidemiological studies have shown the link between obesity and pancreatic cancer. 11, 18 A large population-based casecontrol study of pancreatic cancer demonstrated that obesity was associated with a statistically significant 50% to 60% increased risk of pancreatic cancer. There was also a statistically significant positive trend in risk with increasing caloric intake, with subjects in the highest quartile of caloric intake experiencing a 70% higher risk than those in the lowest quartile. 19 The Metabolic Syndrome and Cancer Project was a large study with 577,315 individuals to investigate the components of metabolic syndrome on the association with overall and site-specific cancer risk. During the 12 years of follow-up, 315 women and 547 men were diagnosed with pancreatic cancer. Among women, obesity was found to increase the risk of pancreatic cancer (adjusted relative risk, 1.54; 95% confidence interval [CI], 1.04-2.29). However, this correlation was not seen in men. 20 Pooled data from the National Cancer Institute Pancreatic Cancer Cohort Consortium also revealed a positive association between increasing BMI and risk of pancreatic cancer (adjusted odds ratio for the highest vs lowest BMI quartile, 1.33; 95% CI, 1.12-1.58; P <.001). 18 A case-control study of 841 patients with pancreatic adenocarcinoma and 754 healthy individuals showed that individuals who were overweight or obese from the ages of 20 to 49 years had an earlier onset of pancreatic cancer by 2 to 6 years (median age of onset was 64 years for patients with normal weight, 61 years for overweight patients [P = 0.02], and 59 years for obese patients [P < 0.001]). Overweight status or obesity during early adulthood is also associated with a greater risk of pancreatic cancer and obesity later in life and a lower overall survival in patients with pancreatic cancer. 21 In a multicenter cohort study in Sweden, obesity was also found to be related to worse pancreatic cancer prognosis. 22 Animal studies have provided strong evidence to link obesity to increased pancreatic cancer risk. A mouse model of pancreatic cancer by overexpressing constitutively active KrasG12D selectively using pancreatic specific Cre drivers led to pancreatic intraepithelial neoplasia (PanIN) development as early as 2 weeks. 23 Fed with normal chow, only 10% of pancreatic ducts developed PanIN-1a lesions at 3 months of age. However, when these mice were fed with high-fat, high-calorie diet and became obese, a significantly bigger portion (45%) of ductal cells developed PanINs, suggesting that obesity expedited the progression of pancreatic cancer. 24 
PUTATIVE MECHANISMS OF THE OBESITY-PANCREATIC CANCER LINK
Several mechanisms have been proposed to explain the increased cancer risk by obesity, including inflammation, insulin resistance, circulating lipids, cytokines, and changes in microbiome. Chronic inflammation is a known major risk factor for many cancers such as esophageal adenocarcinoma, gastric cancer, colorectal cancer, and hepatic cellular carcinoma. [25] [26] [27] It is also well established that chronic pancreatitis is a major risk factor for pancreatic cancer. 28, 29 A hallmark of obesity is adipose tissue inflammation, which can promote cancer growth through the secretion of pro-inflammatory cytokines. Adipose tissue contains (pre-)adipocytes, immune cells, fibroblasts, endothelial cells, and stem/ progenitor cells, many of which can release a variety of proinflammatory cytokines, for example, tumor necrosis factor α, transforming growth factor β, interleukin-6, and leptin. Those factors can in turn stimulate cancer cell proliferation. 30 More recently, the cancer-associated adipocyte has gained attention in the pathogenesis of breast cancer. Dirat et al 31 have shown that breast cancer induces peritumoral adipocytes, named cancerassociated adipocytes, to secret pro-inflammatory factors, which can reciprocally induce more aggressive breast cancer cells. Hertzer et al 32 demonstrated that conditional KrasG12D mice fed a high-fat, high-calorie diet displayed a robust inflammation in the peripancreatic adipose tissue with an elevation of pro-inflammatory cytokines, suggesting an important role of obesity-induced adipose tissue inflammation in pancreatic cancer development.
There is great interest in the role of intestinal microbes in obesity. It has been postulated that intestinal microbes contribute to the regulation of energy homeostasis and fat storage and may play a role in obesity. 33, 34 Obesity has been associated with altered gut microbiota composition, reduced microbial diversity, and reduced gene richness. 35 In the small intestine of genetically susceptible KrasG12D mice, a high-fat diet (HFD) promoted tumor growth, independently of obesity. 36 The transfer of fecal samples from HFD-fed mice with intestinal tumors to healthy adult KrasG12D mice was sufficient to transmit disease in the absence of an HFD. Furthermore, treatment with antibiotics completely blocked HFDinduced tumor progression. These findings suggested that changes in the microbiota play a pivotal role in carcinogenesis and tumorigenesis may be transmissible among genetically predisposed individuals. 36 Obesity is also often associated with insulin resistance and type 2 diabetes mellitus, with elevated levels of insulin and insulin-like growth factor 1 (IGF-1). Diabetes has been associated with increased cancer risk. [37] [38] [39] Epidemiology studies have shown that every 10 mg/mL increase in fasting blood glucose is associated with 14% increase in pancreatic cancer. 39 Increased insulin/ IGF-1 signaling is also known to contribute to cancers such as Ewing sarcoma, breast, ovarian, and lung cancers. [40] [41] [42] Expression levels of both insulin receptor and insulin-like growth factor receptor are increased in many cancers. 43 Insulin receptor and insulin-like growth factor receptor share a significant sequence homology and can function as heterodimers, which bind both IGF-1 and IGF-2. Overactivation of these pathways can activate the Ras/ERK pathway and cause increased cell division. Insulinlike growth factor 1 pathway can also stimulate the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathways, which stimulate proliferation and inhibit apoptosis. [44] [45] [46] On the other hand, overactivation of IGF-1 can further downregulate cellcycle tumor suppressors such as phosphatase and tensin homolog. 47 Antidiabetes medications have great potential in decreasing risks of pancreatic cancer and prolonging pancreatic cancer patient survival. 48, 49 Metformin, a widely used oral diabetic medication, decreases the serum insulin and IGF-1 level. 50, 51 At the molecular level, it inhibits the adenosine monophosphate-directed protein kinease pathway indirectly by inhibiting the complex I of the mitochondrial electron transport chain during oxidative phosphorylation. 46, 52 In vitro studies have shown that metformin inhibits pancreatic cancer cell growth and downregulates mTOR/Sp6 expression level. 53 
ROLE OF WEIGHT LOSS IN PANCREATIC CANCER PREVENTION
Intentional weight loss has been shown to reduce cancer incidence in women, particularly postmenopausal breast cancer and endometrial cancer. 54, 55 However, most of these studies were observational. Calorie restriction in animal models has been shown to slow pancreatic cancer growth and development. In a pancreatic cancer xenograft model, calorie restricted C57BL/6 mice weighed less and had smaller tumors compared with those mice fed with control diet. Similar calorie restricted effects on tumor growth were observed in nude mice transplanted with MIA PaCa-2 human pancreatic tumor cell line. 56 In another study using conditional KrasG12D mice, both intermittent calorie restriction and chronic calorie restriction reduced the percentage of PanIN-3 lesions compared with the ad libitum group. 57 Calorie restriction can lead to short-term weight loss for obese patients. However, the vast majorities of those patients are not able to keep the calorie restriction in the long term and usually gained the lost weight back. Many experts advocate biologically based interventions with new antiobesity drugs and bariatric surgery to treat obesity. 58 Obese patients frequently have comorbidities such as hypertension, hyperlipidemia, type 2 diabetes mellitus, and cardiovascular disease. Bariatric surgery offers long-term and durable weight loss as well as comorbidity resolution. 59 There are several different bariatric surgery techniques, such as Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic gastric banding. Substantial weight loss (roughly 25% from initial body weight for Roux-en-Y gastric bypass) has been reported with up to 20-year follow-up. 60 Roux-en-Y gastric bypass is the criterion standard for modern bariatric surgery and can lead to sustained long-term weight loss. A meta-analysis showed that the mean sample-size weighted percentage of excess weight loss for gastric bypass was 65.7% (n = 3544) versus 45.0% (n = 4109) for gastric band. 61 Because of its high longterm complication rate and inferior weight loss, the use of gastric band has significantly decreased in recent years. 62 Recently, laparoscopic sleeve gastrectomy has been widely accepted as the most popular and definitive bariatric procedure in United States because of the technical simplicity, low complication rate, and excellent weight loss. 62, 63 Interestingly, a few retrospective clinical studies have shown that bariatric surgery reduced the incidence of multiple cancers including breast, endometrial, colorectal, melanoma, and nonHodgkin lymphoma. McCawley et al 64 examined women who underwent bariatric surgery at a single university hospital in Virginia from 1990 to 2006 and found that the incidence of breast, endometrial, and cervical cancers were significantly lower in the bariatric surgery group than the control group (3.6% vs 5.8% in overall cancer incidence). Christou et al 65 analyzed 1035 bariatric surgery (mostly gastric bypass) patients from 1986 to 2002 in Canada and found that bariatric surgery reduced the incidence of many cancers but only to a significant level for breast cancer. Adams et al 66 analyzed 6956 gastric bypass patients in the state of Utah over a 24-year follow-up period. The total cancer incidence was significantly lower in the surgical group compared with controls (hazard ratio [HR], 0.76; 95% CI, 0.65-0.89). Cancer mortality was 46% lower in the surgery group compared with controls (HR, 0.54; 95% CI, 0.37-0.78). 66 The Swedish Obesity Subjects study also examined the risks of cancer reduction after bariatric surgery and found that the number of firsttime cancers was lower in the surgery group (n = 117) than in the control group (n = 169; HR, 0.67; 95% CI, 0.53-0.85). In women, the number of first-time cancers was lower in the surgery group (n = 79) than in the control group (n = 130; HR, 0.58; 95% CI, 0.44-0.77), whereas there was no effect of surgery in men (38 in the surgery group vs 39 in the control group; HR, 0.97; 95% CI, 0.62-1.52). 67 Although those studies have consistently showed a decreased cancer risks and mortality after bariatric surgery, whether or not weight loss caused by bariatric surgery can decrease the risks of pancreatic cancer is still unclear. In the Virginia study, no pancreatic cancer occurred in the bariatric surgery group patients and the study did not mention the incidence of pancreatic cancer in the control group. 64 In the Canadian study, pancreatic cancer was found in 1 (0.1%) of 1035 surgery patients and 19 (0.33%) of 5746 control patients. The relative risk was 0.29 (95% CI, 0.039-2.175), and P value was 0.1666. 65 In the Utah study, there were 9 pancreatic cancer cases in 6596 surgical patients and 8 pancreatic cancer cases in 9442 control group patients and no difference was found. 66 The Swedish Obesity Subjects study did not list each cancer type, and it was impossible to know the incidence of pancreatic cancer in that study. 45 Multicenter studies with longer follow-up are needed to investigate whether or not there is a decreased incidence of pancreatic cancer after bariatric surgery.
MECHANISMS OF BARIATRIC SURGERY ON CANCER RISK REDUCTION
There are several possible mechanisms whereby bariatric surgery may reduce the cancer risk. Bariatric surgery can reduce secretion of inflammatory cytokines. In obese diabetic patients, bariatric surgery caused a significant decrease of inflammatory markers including C-reactive protein, interleukin-6, and tartrateresistant acid phosphatase 5a. 68 Bariatric surgery also has been shown to reduce tissue inflammation. 69, 70 Schneck et al 69 performed sleeve gastrectomy on 33-week-old diet-induced obese C57BI/6 J mice. There were significantly decreased activated T cells ratio and increased anti-inflammatory regulatory T cells in epididymal adipose tissue 3 weeks after surgery. 69 Bariatric surgery leads to significantly improved insulin resistance. Lim et al found that among patients with T2DM who underwent a very low calorie diet or gastric bypass surgery, the hepatic fat content decreased rapidly in parallel with improved hepatic insulin sensitivity and normalization of fasting plasma glucose levels within 7 days. 71 Bariatric surgery also improves intestinal microbiota profile. It has been postulated that intestinal microbes contribute to the regulation of energy homeostasis and fat storage and may play a role in obesity. 33, 34 Obesity has been associated with altered gut microbiota composition, reduced microbial diversity, and reduced gene richness. 35 Both Roux-en-Y gastric bypass and vertical banded gastroplasty induced similar and durable changes on the gut microbiome that were not dependent on body mass index and resulted in altered levels of fecal and circulating metabolites compared with obese controls. 72 Fecal transplantation from these bariatric surgery patients also altered microbiota deposition in germ-free recipient mice. 72 In summary, studies have consistently demonstrated a significantly reduced cancer incidence and/or mortality after bariatric surgery. The possible mechanisms are outlined in Figure 1 . However, because of the relatively small sample size and short follow-up duration, published retrospective studies were not able to detect a difference in pancreatic cancer risk. Increased inflammation, cytokine secretion, altered microbiome, and insulin resistance have all been implicated in the development of obesity related pancreatic cancer. [28] [29] [30] [32] [33] [34] [35] [36] Clinical and experimental data showed clearly that bariatric surgery can lead to decreased tissue inflammation and adipokine secretion, improved microbiome, and decreased insulin resistance. 69, 70, [72] [73] [74] Although no epidemiology studies have ever shown a definitive decrease of pancreatic cancer incidence after bariatric surgery due to the small sample size, we speculate that bariatric surgery could lead to a significant decrease of pancreatic cancer incidence (Fig. 1) . Large, multicenter studies with longer follow-up time may help us to answer this important question in the next 5 to 10 years. Welldesigned animal studies may help us to explore the role and mechanisms of bariatric surgery in pancreatic cancer prevention.
FUTURE RESEARCH DIRECTIONS
More studies are greatly needed to prove that weight loss and/or bariatric surgery can reduce the risk of developing pancreatic cancer. Animal bariatric surgery models have been established, and they can be used to test if bariatric surgery can reverse PanIN progression. Calorie restriction and/or bariatric surgery in animal pancreatic cancer models are also very useful to elucidate the pancreatic cancer prevention mechanisms by weight loss. A few large health maintenance organizations (HMOs) in United States such as Kaiser Permanente have large number of obese patients undergoing bariatric surgery every year and a significant portion of those patients will have follow-up with the same HMO. It is possible that the bariatric databases from those HMOs will have more than 10,000 bariatric patients who have been followed for more than 10 years in the near future. That data will be very valuable to assess if bariatric surgery can decrease pancreatic cancer and other cancer risk. Eventually, prospective multicenter studies with large number of bariatric patients and long-term follow-up will definitively establish the relationship between weight loss and pancreatic cancer prevention. 
CONCLUSIONS
Obesity has become an endemic in the past few decades and is associated with increased cancer incidence, mortality, and health cost. In particular, obesity increases the risk of pancreatic cancer, possibly through multiple mechanisms such as inflammation, insulin resistance, and altered intestinal microbiota. As a modifiable risk factor, obesity can be managed with a multidisciplinary approach. Bariatric surgery has been shown to lead to durable weight loss in the long term and reduce risks of many cancers. It is important to further study the effect of weight loss on the risk reduction of pancreatic cancer, one of the most deadly solid cancers.
